Latest News & Features
Americas
The first US court decision applying the Myriad decision has landed, and it makes for interesting reading, as Antoinette Konski reports. 3 December 2013
Americas
How can ‘big’ data help drug candidates through the pipeline? And who does the data belong to? LSIPR spoke to NuMedii chief executive Gini Deshpande. 3 December 2013
Biotechnology
Ethical considerations plus the ambiguity of the Biotech Directive are factors influencing the patentability of totipotent stem cells, says Andrew Sanderson. 4 November 2013
Europe
Genomic Vision develops genetic screening tests for diagnostics and research. In the aftermath of the Myriad ruling, how can it use IP to develop market share? LSIPR spoke to chief executive Aaron Bensimon to find out. 4 November 2013
Asia
Many of the world’s biggest selling drugs have lost exclusivity in recent years, presenting huge opportunities for generic drugs companies but, as LSIPR finds out, it doesn’t have to be a dead end for the innovators. 16 October 2013
Biotechnology
Frances Salisbury and Lindsey Woolley look at the complex business of patenting agricultural products in Europe. 16 October 2013
Biotechnology
The Court of Justice of the European Union’s decision in the Brüstle case has worrying implications for some stem cell patents. Andy Sanderson looks at the landscape across Europe. 16 October 2013
Americas
In the life sciences sector, defending broad patent claims can be a tricky business, says Gordon Wright. 16 October 2013
Biotechnology
When it comes to plants, European courts have been occupied with various debates over salad. Margreet van Heuvel and Bart Swinkels take a look. 16 October 2013
Americas
In Mexico, it can be tricky to protect data exclusivity, but prospective international agreements may provide a solution, as Jose Trigueros explains. 16 October 2013